For the year, AstraZeneca PLC's sales in emerging markets sales were up 12% at constant currencies (8% actual) to $5,827 million, driven in large part by China, where business surged by 22% (at constant currency and in actual terms) to $2,242 million.
"Our strong performance in emerging markets is a particular highlight, with China becoming our second largest national market," CEO Pascal Soriot told a results briefing